We help providers deliver more accessible genetic services to the patients they serve
Find out how our and genetic experts and services can help your organization
Learn more about our areas of expertise
Learn more about how we help you deliver more genetic services to more patients
We do it because we want to make precision medicine actionable to improve lives
We support hospitals and health systems, biopharmaceutical organizations, and genetic testing labs
Find out how our genetic experts can help your organization
We help you expand your genetic services to more patients to improve health outcomes
Navigate Genetic Testing and Counseling with Confidence
View our case studies to see how we’ve helped our partners achieve results.
Home » Who is Calcilytix?
Calcilytix is a clinical-stage biopharmaceutical company focused on developing a targeted therapy for disorders of calcium homeostasis. Our product candidate, encaleret, is an investigational orally-administered small molecule designed to specifically inhibit the calcium-sensing receptor, hypothesized to restore normal serum calcium and lower urine calcium in patients with abnormal Calcium-Sensing Receptors (CaSRs).
Calcilytix is led by a team of industry veterans who have been responsible for developing over 30 molecules through Initial New Drug (IND) applications and more than 10 approved drugs. Together with physicians and patients, we aim to develop an effective treatment option for patients with hypopara and Autosomal Dominant Hypocalcemia Type 1 (ADH1).